Drug intelligence / Profile preview

IBI314

Development stage: Discontinued
Lead developer: Suzhou Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI314 is an investigational, fixed 1:1 cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies, P5-22 and P14-44, developed by Innovent for treatment of COVID-19. The antibodies bind distinct, non-overlapping epitopes within the receptor-binding domain of the SARS-CoV-2 spike glycoprotein, blocking spike interaction with host ACE2 and thereby preventing viral cell entry. It was evaluated as a single intravenous infusion in Phase 1/2 COVID-19 studies, which were terminated. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9183246/))

Brand names: IBI314IBI-314IBI 314
Other names: IBI 314IBI314IBI-314P5-22 + P14-44

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)

Beyond the preview

Go deeper on IBI314.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI314.

Explore the full profile